Attention deficit hyperactivity disorder, inattentive type
diseaseOn this page
Also known as ADDattention deficit disorderattention deficit hyperactivity disorder, inattentive/distractible typeattention deficit hyperactivity disorder, predominantly inattentive type
Summary
Attention deficit hyperactivity disorder, inattentive type (MONDO:0005302) is a disease and 65 clinical trials. Top therapeutic interventions include guanfacine, methylphenidate, and lisdexamfetamine. A subtype of attention deficit-hyperactivity disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 65
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | attention deficit hyperactivity disorder, inattentive type |
| Mondo ID | MONDO:0005302 |
| MeSH | D001289 |
| DOID | DOID:1094 |
| NCIT | C35092 |
| SNOMED CT | 406506008 |
| UMLS | C0339002 |
| MedGen | 473060 |
| Is cancer (heuristic) | no |
Also known as: ADD · attention deficit disorder · attention deficit hyperactivity disorder, inattentive/distractible type · attention deficit hyperactivity disorder, predominantly inattentive type
Disease family
This is a subtype of attention deficit-hyperactivity disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › developmental disorder of mental health › specific developmental disorder › attention deficit-hyperactivity disorder › attention deficit hyperactivity disorder, inattentive type
Related subtypes (2): hereditary attention deficit-hyperactivity disorder, attention deficit-hyperactivity disorder 8
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 65.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 42 |
| PHASE3 | 7 |
| PHASE4 | 5 |
| PHASE2 | 4 |
| PHASE1 | 3 |
| EARLY_PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06248229 | PHASE4 | RECRUITING | A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD). |
| NCT00261872 | PHASE4 | COMPLETED | Treatment of Patients With Alcoholism and Attention Deficit Disorder |
| NCT01156051 | PHASE4 | TERMINATED | Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia |
| NCT02048241 | PHASE4 | COMPLETED | Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder |
| NCT02712996 | PHASE4 | COMPLETED | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children |
| NCT00048360 | PHASE3 | COMPLETED | Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults |
| NCT01000064 | PHASE3 | TERMINATED | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits |
| NCT01883817 | PHASE3 | COMPLETED | Effect of Omega-3 Fatty Acid on Cortical Function in ADHD |
| NCT03605680 | PHASE3 | COMPLETED | A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder |
| NCT03605836 | PHASE3 | COMPLETED | A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder |
| NCT03605849 | PHASE3 | COMPLETED | A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder |
| NCT03662763 | PHASE3 | COMPLETED | Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity |
| NCT05243186 | PHASE2/PHASE3 | UNKNOWN | Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill |
| NCT00919906 | PHASE1/PHASE2 | COMPLETED | My Scrivener® - Measuring Effectiveness and Dose Response in Children |
| NCT02156089 | PHASE2 | TERMINATED | Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial |
| NCT02225106 | PHASE2 | COMPLETED | Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI |
| NCT02635035 | PHASE2 | COMPLETED | Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT |
| NCT05200936 | PHASE2 | COMPLETED | Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial |
| NCT00417794 | PHASE1 | COMPLETED | Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD |
| NCT01369459 | PHASE1 | COMPLETED | Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder |
| NCT04729439 | PHASE1 | UNKNOWN | Technology-Enhanced Executive Functioning Intervention for ADHD |
| NCT01856686 | EARLY_PHASE1 | COMPLETED | Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein |
| NCT02614599 | EARLY_PHASE1 | COMPLETED | Neurocognitive and Neurobiological Improvement in ADHD Children With High Protein Diet |
| NCT05354232 | Not specified | RECRUITING | Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD) |
| NCT05927974 | Not specified | RECRUITING | Investigating Dynamic Interactions in Distributed Cognitive Control Networks |
| NCT06194162 | Not specified | RECRUITING | Weighted Blankets for Sleep Disturbance Among Children With ADHD |
| NCT06594536 | Not specified | NOT_YET_RECRUITING | Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity |
| NCT06797570 | Not specified | NOT_YET_RECRUITING | The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years. |
| NCT07136259 | Not specified | NOT_YET_RECRUITING | A Quick and Reliable Eye Movement Test to Help Diagnose ADHD in Children. |
| NCT07217977 | Not specified | ENROLLING_BY_INVITATION | An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD |
| NCT07341204 | Not specified | NOT_YET_RECRUITING | How Virtual Reality Can Help Neurodivergent Children Improve Their Attention |
| NCT07419659 | Not specified | ENROLLING_BY_INVITATION | Effects of Lactic Acid Bacteria in Patients With Attention-Deficit/Hyperactivity Disorder |
| NCT07465081 | Not specified | RECRUITING | Ultra-processed Food Consumption and Behavioral Disorder and Cognitive Function |
| NCT00014898 | Not specified | COMPLETED | Attention Deficit Disorder and Exposure to Lead |
| NCT00330434 | Not specified | WITHDRAWN | Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism |
| NCT00372359 | Not specified | UNKNOWN | Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions |
| NCT00776737 | Not specified | COMPLETED | Studies of Measures of Attention |
| NCT01130467 | Not specified | UNKNOWN | Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder |
| NCT01154686 | Not specified | UNKNOWN | Working Memory Training in College Students With Attention-Deficit Hyperactivity Disorder/Learning Disabilities |
| NCT01184235 | Not specified | COMPLETED | Multidimensional Measurement of Psychopharmacological Treatment Response |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| GUANFACINE | 4 | 6 |
| METHYLPHENIDATE | 4 | 6 |
| LISDEXAMFETAMINE | 4 | 4 |
| AMPHETAMINE | 4 | 2 |
| ARTENIMOL | 4 | 1 |
| DEXMETHYLPHENIDATE | 4 | 1 |
| DEXTROAMPHETAMINE | 4 | 1 |
| LEVAMFETAMINE | 4 | 1 |
| DOCONEXENT | 3 | 1 |
| PARAFFIN | 3 | 1 |
| SULFORAPHANE | 3 | 1 |